[{"orgOrder":0,"company":"Phillips - Medisize","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Lanreotide Acetate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Phillips - Medisize","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Phillips - Medisize \/ Phillips-Medisize","highestDevelopmentStatusID":"12","companyTruncated":"Phillips - Medisize \/ Phillips-Medisize"}]

Find Clinical Drug Pipeline Developments & Deals by Phillips - Medisize

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Ipsen’s extensive experience with Somatuline Autogel / Somatuline Depot has offered deep insights into the challenges of living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly.

                          Brand Name : Somatuline Autogel

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          March 16, 2022

                          Lead Product(s) : Lanreotide Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Ipsen

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank